H.C. Wainwright reiterates buy rating on Exelixis stock at $47

Exelixis (NASDAQ:EXEL) saw its partner Ipsen receive a positive European CHMP opinion for CABOMETYX in treating specific neuroendocrine tumors, a critical step towards EU market approval that reinforces the drug's revenue potential. This development, based on compelling Phase 3 data, underpins H.C. Wainwright's maintained Buy rating and $47 price target, reflecting Exelixis' strong financial position and 24.5% revenue growth. Concurrently, the company's zanzalintinib pipeline generated mixed but generally positive analyst sentiment, with several firms raising price targets following promising trial results in colorectal and renal cell carcinoma, despite some noted caution regarding adverse events.

Analysis

Exelixis (EXEL) has received a significant positive catalyst with the European Medicine Agency's CHMP recommending approval for its drug, CABOMETYX, in treating specific neuroendocrine tumors. This recommendation, based on a Phase 3 trial halted early for superior efficacy, strongly positions the drug for final European Commission approval, reinforcing its revenue growth trajectory. The company's financial health appears robust, underscored by 24.5% revenue growth over the last twelve months, a perfect Piotroski Score of 9, and upward earnings revisions from eight analysts. Concurrently, Exelixis's pipeline asset, zanzalintinib, is eliciting bullish sentiment, prompting price target increases from Citizens JMP, H.C. Wainwright, and BofA Securities to $50, $47, and $46 respectively, following promising data in renal cell and colorectal cancers. However, this optimism is tempered by caution from Stifel, which maintains a Hold rating with a $38 target, citing a higher rate of adverse events in zanzalintinib trials, a sentiment partially echoed by BofA's reservations about success in the broader colorectal cancer population.

Key Decisions for Investors

• Investors should view the positive CHMP opinion for CABOMETYX as a significant de-risking event that increases the probability of near-term European revenue expansion, warranting a potential upward revision of revenue forecasts.
• Given the company's strong fundamentals, including 24.5% revenue growth and a perfect Piotroski score, alongside multiple analyst upgrades, the current valuation may present a compelling entry point for those bullish on the oncology pipeline.
• It is crucial to monitor upcoming clinical data for the zanzalintinib pipeline, particularly regarding its adverse event profile and efficacy in the broader colorectal cancer population, as these factors represent the primary risks highlighted by more cautious analysts.